乙酸-(2,4,6,N-四甲基苯胺) | 40752-00-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 乙酸-(2,4,6,N-四甲基苯胺)
• 英文名称: N-mesityl-N-methylacetamide
• 英文别名: acetic acid-(2,4,6,N-tetramethyl-anilide)；N-Methyl-acetmesidid；Essigsaeure-(2,4,6,N-tetramethyl-anilid)；Essigsaeure-methylmesidid；N-methyl-N-(2,4,6-trimethylphenyl)acetamide
• CAS: 40752-00-9
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: JXGVBIBIKLZHJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  乙酸-(2,4,6,N-四甲基苯胺) 在 dimethyl sulfide borane 、 甲醇 作用下， 以 四氢呋喃 为溶剂， 反应 3.08h， 生成 2,4,6-三甲基-N-甲基苯胺
  参考文献：
  名称：

  [EN] HIV REVERSE TRANSCRIPTASE INHIBITORS
  [FR] INHIBITEURS DE LA TRANSCRIPTASE INVERSE DU VIH

  摘要：

  公式（I）的化合物是HIV逆转录酶抑制剂，其中T为O或S；U为O、S、N（R4）或直接键连接V至C（=T）基团；V为可选择取代的C1-6烷基；W为C（O）N（R5）或直接键连接V至R3；R1、R2、R3、R4和R5在此处有定义。公式（I）的化合物及其药学上可接受的盐在抑制HIV逆转录酶、预防和治疗HIV感染以及预防、延缓AIDS发病和治疗方面是有用的。这些化合物及其盐可作为药物组合物中的成分，可选择地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。

  公开号：

  WO2006037468A1
• 作为产物：
  描述：

  N,N,2,4,6-五甲基苯胺 在 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 生成 乙酸-(2,4,6,N-四甲基苯胺)
  参考文献：
  名称：

  Volz,H.; Ruchti,L., Justus Liebigs Annalen der Chemie, 1972, vol. 763, p. 184 - 197

  摘要：

  DOI：

文献信息

• C–H Borylation by Platinum Catalysis
  作者：Takayuki Furukawa、Mamoru Tobisu、Naoto Chatani

  DOI：10.1246/bcsj.20160391

  日期：2017.3.15

  platinum-catalyzed borylation of aromatic C–H bonds. N-Heterocyclic carbene-ligated platinum catalysts are found to be efficient catalysts for the borylation of aromatic C(sp2)–H bonds when bis(pinacolato)diboron is used as the boron source. The most remarkable feature of these Pt catalysts is their lack of sensitivity towards the degree of steric hindrance around the C–H bonds undergoing the borylation reaction

  在此，我们描述了铂催化的芳族 C-H 键硼化。当使用双（频哪醇）二硼作为硼源时，发现 N-杂环卡宾连接的铂催化剂是芳族 C(sp2)-H 键硼化的有效催化剂。这些 Pt 催化剂最显着的特点是它们对发生硼化反应的 C-H 键周围的空间位阻程度缺乏敏感性。这些 Pt 催化剂允许合成空间拥挤的 2,6-二取代苯基硼酸酯，否则使用现有的 C-H 硼酸化方法难以合成。此外，铂催化允许氟芳烃系统中氟取代基邻位的 C-H 键的位点选择性硼化。
• 化合物、着色組成物、インクジェット記録用インク、インクジェット記録方法、インクジェットプリンタカートリッジ、及びインクジェット記録物
  申请人：富士フイルム株式会社

  公开号：JP2015193801A

  公开（公告）日：2015-11-05

  【課題】印画濃度、耐光性、耐オゾン性、及び耐湿性が優れた画像を形成することができる化合物、着色組成物、インクジェット記録用インク、インクジェット記録方法、インクジェットプリンタカートリッジ、及びインクジェット記録物を提供する。【解決手段】一般式（１）で表される化合物。（Ｒ２、Ｒ４、Ｒ７及びＲ９の少なくとも１つはアシルアミノ基；Ｒ１〜Ｒ１０及びＲ１１１〜Ｒ１２０の少なくとも１つはイオン性親水性基）【選択図】なし

  题目：提供一种能够形成印刷浓度、耐光性、耐臭氧性和耐潮湿性优良图像的化合物、着色组合物、喷墨打印用墨水、喷墨打印方法、喷墨打印机墨盒和喷墨打印物。 解决方案：提供一种由通式（1）表示的化合物。（其中，至少有R2、R4、R7和R9中的一个是酰胺基；至少有R1〜R10和R111〜R120中的一个是离子性亲水基）【无选图】
• Mechanism of Reaction of an Arenediazonium Ion in Aqueous Solutions of Acetamide, <i>N</i>-Methylacetamide, and <i>N</i>,<i>N</i>-Dimethylacetamide. A Potential Method for Chemically Tagging Peptide Bonds at Aggregate Interfaces
  作者：Laurence S. Romsted、Jianbing Zhang、Lanzhen Zhuang

  DOI：10.1021/ja980556a

  日期：1998.10.1

  The mechanism of dediazoniation of 2,4,6-trimethylbenzenediazonium ion, 1-ArN2+, in concentrated aqueous solutions of acetamide, N-methylacetamide, and N,N-dimethylacetamide (peptide bond models) was probed by a combination of techniques including HPLC, GC/MS, and (H2O)-O-18 isotopic labeling. The kinetics and product distributions are completely consistent with the heterolytic dediazoniation mechanism, i.e., rate-determining loss of N-2 followed by trapping of the aryl cation intermediate, 1-Ar+, by H2O and the oxygens and nitrogens of the amides. Aryl imidates formed from trapping by amide O hydrolyze rapidly into aryl ester/amine and amide/phenol product pairs. The results were used to estimate the selectivity of 1-Ar+ toward the amide oxygens and nitrogens versus H2O. 1-Ar+ is only 10-40% more selective toward H2O than amide O, but it is more than 10 times mon selective toward H2O than the amide N. 1-Ar+ is slightly more selective toward the N of acetamide than N-methylacetamide. However, within the HPLC detection limit, 1-Ar+ does not give a product from reaction with the N,N-dimethylacetamide nitrogen. The selectivities are interpreted by using a preassociation model, i.e., selective solvation by the different nucleophiles of the reactive diazonio group in the ground state. These results indicate that chemical tagging (trapping by N) and cleaving (trapping by O) of the peptide bonds and the weakly basic side chains of polypeptides and proteins bound to association colloids, vesicles and biomembranes, and emulsions may provide new information on their topologies and orientations at the aggregates' interfaces.
• Pancreatic involvement in von Hippel–Lindau disease
  作者：Pascal R. Hammel、Valerie Vilgrain、Benoit Terris、Alfred Penfornis、Alain Sauvanet、Jean–Michel Correas、Dominique Chauveau、Axel Balian、Catherine Beigelman、Dermot O'Toole、Pierre Bernades、Philippe Ruszniewski、Stephane Richard

  DOI：10.1053/gast.2000.18143

  日期：2000.10

  Background & Aims: Pancreatic involvement in von Hippel-Lindau (VHL) disease, agenetic disorder with a dominant mode of inheritance affecting various organs, has rarely been studied, We assessed the prevalence, type of lesions, natural history, and impact of pancreatic involvement In patients with VHL, Methods: A total of 158 consecutive patients from 94 families with VHL disease were studied in a prospective French collaborative study, All patients underwent systematic screening for VHL lesions, including computerized tomography (CT) scanning of the pancreas reviewed by an experienced radiologist, Clinical data, investigations, and treatments performed were also reviewed, Results: Pancreatic involvement was observed in 122 patients (77.2%) and included true cysts (91.1%),serous cystadenomas (12.3%), neuroendocrine tumors (12.3%), or combined lesions (11.5%), The pancreas was the only organ affected in 7.6% of patients, Patients with pancreatic lesions had fewer pheochromocytomas than those without (14/122 vs, 16/36; P < 0.0001), and patients with neuroendocrine pancreatic tumors had venal involvement less often than those without (8/99 vs, 6/20; P = 0.013), None of the patients With neuroendocrine tumors had symptoms of hormonal hypersecretion. Pancreatic lesions evolved in half of patients but required specific treatment in only 10 (8.2%) when they were symptomatic or for the resection of large neuroendocrine tumors, Conclusions: Pancreatic involvement is seen in most patients with VHL disease. Although symptoms are rare, specific treatment of pancreatic lesions is required in selected patients, mainly those with neuroendocrine tumors.